Gene Technologies for Medicines: Public and Business Demands


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

At the present time, gene technologies play a key part in the development of new approaches to the diagnostics and therapy of diseases. Russian scientists have already successfully introduced efficient preparations based on multiclonal antibodies into practice and have advanced developments in the fields of CAR-T therapy and gene-therapy preparations on the basis of recombinant adenoassociated viruses. Some gene diagnostic tools, which essentially improve the efficiency of medical care due to the personalized approach to the therapy of diseases, are also put into practice. The successful introduction of innovative technologies and contemporary methods of diagnostics and therapy is impossible without cooperation between academic science and business. The companies providing the conditions for cooperation with academic science and engagement of specialists of different profiles have hastened the mass introduction of gene technologies and, therefore, the defeat over many earlier incurable socially significant diseases.

作者简介

D. Morozov

BIOCAD Biotechnological Company, poselok Strel’na

编辑信件的主要联系方式.
Email: morozov@biocad.ru
俄罗斯联邦, St. Petersburg, 198515

R. Ivanov

BIOCAD Biotechnological Company, poselok Strel’na

编辑信件的主要联系方式.
Email: ivanov@biocad.ru
俄罗斯联邦, St. Petersburg, 198515

P. Gershovich

BIOCAD Biotechnological Company, poselok Strel’na

编辑信件的主要联系方式.
Email: gershovich@biocad.ru
俄罗斯联邦, St. Petersburg, 198515

N. Pestova

BIOCAD Biotechnological Company, poselok Strel’na

编辑信件的主要联系方式.
Email: pestova@biocad.ru
俄罗斯联邦, St. Petersburg, 198515

M. Petrova

BIOCAD Biotechnological Company, poselok Strel’na

编辑信件的主要联系方式.
Email: petrovamv@biocad.ru
俄罗斯联邦, St. Petersburg, 198515


版权所有 © Pleiades Publishing, Ltd., 2019
##common.cookie##